Freenome
Freenome raises $254M Series D at $1.2B valuation
Freenome: Series D Funding Round
Freenome has successfully raised $254M in Series D funding, reaching a valuation of $1.2B.
Company Overview
Multi-cancer early detection blood test developer using AI
Funding Details
The Series D round was led by Roche, with participation from a16z Life Sciences, ARK Investments.
Company Information
- Headquarters: South San Francisco, CA
- Founded: 2014
- Employees: 300+
- Category: Biotech
Investment
Freenome plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Roche: Verified investor in Series D
- a16z Life Sciences: Verified investor in Series D
- ARK Investments: Verified investor in Series D
Company Info
Investors (3)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free